Crohn Disease
📧 Sign up to get email alerts when something new happens for Crohn Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-01-18Clinical Trial Update: Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease
A completed clinical trial assessing healthcare resource use, mental health problems, and infections in people with inflammatory bowel disea…
-
FDA approval · 2022-12-13FDA Approved: IDACIO — Original Application (Fresenius Kabi USA, LLC)
FDA approved IDACIO (adalimumab-afcf) from Fresenius Kabi USA, LLC as a biosimilar to adalimumab (Humira) under an original Biologics Licens…
-
CLINICAL_TRIALS trial_result · 2022-12-09Clinical Trial Update: A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease [Phase 2]
A Phase 2 trial evaluating a Janssen investigational therapy for moderately to severely active Crohn's disease was terminated, with results …
-
CLINICAL_TRIALS trial_result · 2022-12-05Clinical Trial Update: Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease [Phase 3]
Phase 3 trial update for Alicaforsen (ISIS 2302) in active Crohn's disease; study completed.
-
CLINICAL_TRIALS trial_result · 2022-11-23Clinical Trial Update: A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies [Phase 3]
Phase 3 trial assessing efficacy and safety of upadacitinib in moderately to severely active Crohn's disease after inadequate response or in…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2022-11-16FDA Approved: MESALAMINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for mesalamine from Teva Pharmaceuticals USA to update the product labeling.
-
FDA approval · 2022-11-16FDA Approved: AZULFIDINE EN-TABS — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for Azulfidine En-Tabs (sulfasalazine) filed by Pfizer Laboratories Div Pfizer Inc.
-
CLINICAL_TRIALS trial_result · 2022-11-16Clinical Trial Update: A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease [Phase 3]
Phase 3 trial updating on etrolizumab for moderately to severely active Crohn's disease; results posted after completion.
-
FDA approval · 2022-10-28FDA Approved: MESALAMINE — Original Application (Alembic Pharmaceuticals Limited)
FDA approved the original application for a generic MESALAMINE product by Alembic Pharmaceuticals Limited.
-
CLINICAL_TRIALS trial_result · 2022-10-18Clinical Trial Update: Exclusive Enteral Nutrition in Patients With Ileocaecal Crohn's Disease [Phase 3]
A Phase 3 clinical trial update evaluating exclusive enteral nutrition in patients with ileocecal Crohn's disease is ongoing, with unclear s…
-
CLINICAL_TRIALS trial_result · 2022-10-14Clinical Trial Update: Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients [Phase 4]
Phase 4 clinical trial updating dosing interval of adalimumab in Crohn's disease patients in remission.
-
CLINICAL_TRIALS trial_result · 2022-09-21Clinical Trial Update: Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease. [Phase 3]
A Phase 3 trial comparing Vedolizumab IV to placebo in Chinese participants with Crohn's disease has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-09-07Clinical Trial Update: Fecal Transplant for Crohn's Disease [Phase 2]
A Phase 2 clinical trial evaluating fecal transplant for Crohn's disease has been completed.
-
CLINICAL_TRIALS trial_result · 2022-09-07Clinical Trial Update: Control Crohn Safe Trial [Phase 4]
Phase 4 clinical trial update for Control Crohn Safe Trial investigating Crohn's disease and inflammatory bowel diseases; currently recruiti…
-
CLINICAL_TRIALS trial_result · 2022-08-15Clinical Trial Update: A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy [Phase 3]
A Phase 3 trial evaluating upadacitinib for moderate-to-severe Crohn's disease in patients inadequately responding or intolerant to biologic…
-
CLINICAL_TRIALS trial_result · 2022-08-15Clinical Trial Update: Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease [Phase 3]
Phase 3 trial update for Alicaforsen (ISIS 2302) in active Crohn's disease has completed.
-
CLINICAL_TRIALS trial_result · 2022-08-12Clinical Trial Update: Safety of Injection of Placental Mesenchymal Stem Cell Derived Exosomes for Treatment of Resistant Perianal Fistula in Crohn's Patients [Phase 1, Phase 2]
A clinical trial update reports safety data for injection of placental mesenchymal stem cell–derived exosomes in Crohn's-associated perianal…
-
CLINICAL_TRIALS withdrawal · 2022-08-09Clinical Trial Update: Exclusive Enteral Nutrition vs. Infliximab in Chinese CD Patients [Phase 4]
A Phase 4 trial comparing Exclusive Enteral Nutrition with infliximab in Chinese patients with Crohn's disease was withdrawn.
-
CLINICAL_TRIALS trial_result · 2022-08-04Clinical Trial Update: Management of Moderate POstoperative Recurrence in Crohn's Disease: a randoMizEd contROLled Trial of Therapeutic Escalation, the POMEROL Trial. (POMEROL) [Phase 4]
Phase 4 randomized controlled trial investigating therapeutic escalation for moderate postoperative recurrence in Crohn's disease (POMEROL t…
-
CLINICAL_TRIALS trial_result · 2022-08-03Clinical Trial Update: A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy [Phase 4]
Phase 4 randomized trial comparing infliximab-antimetabolites combination therapy to anti-metabolites monotherapy and to infliximab monother…
-
CLINICAL_TRIALS trial_result · 2022-07-29Clinical Trial Update: Trial Evaluating the Diagnostic Usefulness of Lumentin® 44 When Used as Contrast Agent [Phase 2]
Phase 2 trial evaluating Lumentin 44 as a diagnostic contrast agent completed for Crohn disease.
-
FDA approval · 2022-07-18FDA Approved: ADALIMUMAB — Supplemental Application (Sandoz Inc)
The FDA approved Sandoz's supplemental application for the adalimumab biosimilar ADALIMUMAB-ADAZ. The approval covers multiple inflammatory …
-
CLINICAL_TRIALS trial_result · 2022-07-06Clinical Trial Update: A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease [Phase 3]
Phase 3 trial evaluating risankizumab for moderately to severely active Crohn's disease has completed with posted results.
-
FDA approval · 2022-06-17FDA Approved: ENTYVIO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for ENTYVIO (vedolizumab) submitted by Takeda Pharmaceuticals America, Inc.
-
CLINICAL_TRIALS trial_result · 2022-06-14Clinical Trial Update: A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment [Phase 3]
Phase 3 trial evaluating risankizumab for moderately to severely active Crohn's disease in patients who failed prior biologic treatment; stu…